NCT03694639

CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome

Status unknown Phase 4 Last updated 7 March 2019

What this trial tests

Phase 4 trial testing ganglion impar block in Pain, Phantom in 40 participants. Status unknown.

Timeline

12 June 2018

Primary endpoint
1 June 2019

29 July 2019

Quick facts

Lead sponsor	Mansoura University
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	40
Start date	12 June 2018
Primary completion	1 June 2019
Estimated completion	29 July 2019
Sites	1 location across Egypt

Drugs / interventions tested

• ganglion impar block

Conditions studied

• Pain, Phantom — all drugs for Pain, Phantom →

Sponsor

Mansoura University

Who can join

Adults 18 to 70, any sex, with Pain, Phantom. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background:Patients underwent abdominoperineal resection with colostomy may suffered from phantom rectum pain syndrome in the perineal area.In this study, the investigators evaluate the combination between ganglion impar block to pregabaline in the treatment of phantom rectal pain syndrome.

Method: Forty patients were randomly allocated into 2 groups: Group A (n=20) where patients received pregabaline 150 mg twice daily. Group B (n=20) where patients received pregabaline 150 mg twice daily plus ganglion impar block using 5 ml bupivacaine 5% with 14 mg/2 ml betamethasone.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.